Non-statin therapies for lowering cholesterol
Pro Research Analysisby 
Searched over 200M research papers
Non-Statin Cholesterol-Lowering Therapies: Key Options and Mechanisms
Several non-statin therapies are now available for lowering cholesterol, especially for patients who cannot tolerate statins or need additional LDL-C reduction. The main non-statin options include ezetimibe, PCSK9 inhibitors (such as evolocumab and alirocumab), bempedoic acid, inclisiran, bile acid sequestrants, fibrates, and icosapent ethyl. Newer agents like evinacumab and gene-based therapies are also emerging as promising alternatives 1234+3 MORE.
Ezetimibe
Ezetimibe works by blocking cholesterol absorption in the intestine. It is often used as an add-on to statins or as monotherapy in statin-intolerant patients. Ezetimibe has shown cardiovascular benefits and is recommended in guidelines for patients who do not reach LDL-C targets with statins alone 1246+2 MORE.
PCSK9 Inhibitors
PCSK9 inhibitors, such as evolocumab and alirocumab, are monoclonal antibodies that significantly lower LDL-C by increasing the liver’s ability to remove cholesterol from the blood. These agents are highly effective, especially when added to maximally tolerated statins, and have demonstrated reductions in cardiovascular events. Inclisiran, a small interfering RNA, also targets PCSK9 and offers similar LDL-C lowering effects with less frequent dosing 1234+5 MORE.
Bempedoic Acid
Bempedoic acid inhibits cholesterol synthesis in the liver through a pathway similar to statins but is not associated with muscle-related side effects. It is effective as monotherapy or in combination with ezetimibe, providing an oral alternative for patients who cannot tolerate statins 1234+2 MORE.
Other Agents
- Bile Acid Sequestrants: These drugs bind bile acids in the intestine, reducing cholesterol absorption. They are now considered secondary options, mainly for patients intolerant to other therapies 36.
- Fibrates and Nicotinic Acid: These are primarily used for lowering triglycerides rather than LDL-C, but may be considered in specific cases .
- Icosapent Ethyl: This omega-3 fatty acid derivative is used as an adjunct to statins in patients with high triglycerides and has shown cardiovascular benefits 2789.
- Evinacumab: An ANGPTL3 monoclonal antibody, evinacumab is effective in patients with refractory hypercholesterolemia 29.
- Gene-Based Therapies: Emerging treatments include antisense oligonucleotides and small interfering RNAs targeting specific lipid-related genes, though these are still under investigation 39.
Efficacy and Clinical Outcomes
Non-statin therapies, especially PCSK9 inhibitors and ezetimibe, have demonstrated significant LDL-C reduction and regression of coronary atherosclerosis when used alone or in combination with statins. The degree of LDL-C lowering is closely linked to the regression of atherosclerotic plaque and reduction in cardiovascular events 1245+2 MORE. Bempedoic acid and inclisiran also show promising results in clinical trials 1234+2 MORE.
Clinical Practice and Utilization
Despite their proven benefits, non-statin therapies remain underutilized in clinical practice. Only a small percentage of patients with atherosclerotic cardiovascular disease receive these agents, highlighting a gap in optimal cholesterol management . Cost and access remain barriers for some patients 24.
Conclusion
Non-statin therapies, including ezetimibe, PCSK9 inhibitors, bempedoic acid, inclisiran, and others, offer effective options for lowering cholesterol and reducing cardiovascular risk, especially for patients who cannot achieve LDL-C targets with statins alone or are statin-intolerant. These agents are safe, effective, and increasingly recommended in clinical guidelines, but greater efforts are needed to improve their uptake in practice to close the treatment gap for high-risk patients 1234+6 MORE.
Sources and full results
Most relevant research papers on this topic